Cephalon Australia Pty. Ltd.

Domantis Limited

Jennifer A Lee

Gregory Paul Winter

Ian M Tomlinson

Benjamin P Woolven

Anthony Gerard Doyle

Philip Anthony Jennings

Steve Holmes

Carolyn Enever

Armin Sepp

Mary Frances Fitzgerald

Rudolf M T De Wildt

Justian Craig Fox

Amrik Basran

Neil D Brewis

Kate Jones

Ruud De Wildt

Stanislas Blein

Stanislas Charles Blein

The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

Antagonists against TNFR1 and methods of use therefor

The present invention provides a recombinant domain antibody (dAb) which binds to human TNF&#x3b1;, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Anti-inflammatory dAb

The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-&#x3b1;, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

The present invention provides a domain antibody construct which binds to human TNF-&#x3b1;, with the construct comprising:

Domain antibody construct

Growing community of inventors

Cambridgeshire, United Kingdom

Jennifer A Lee